Literature DB >> 24046109

Epithelioid sarcoma: need for a multimodal approach to maximize the chances of curative conservative treatment.

Antonin Levy1, Cécile Le Péchoux, Philippe Terrier, Ryan Bouaita, Julien Domont, Olivier Mir, Sarah Coppola, Charles Honoré, Axel Le Cesne, Sylvie Bonvalot.   

Abstract

OBJECTIVE: This study was designed to evaluate the impact of multimodal management on a series of epithelioid sarcoma (ES) patients treated with curative intent.
METHODS: Data were collected on 69 consecutive patients treated from 1982 to 2012. Univariate and multivariate analyses were performed for tumor control and overall survival (OS).
RESULTS: In total, 54 (78 %) patients had localized ES (M0 group). In the M0 group, 85 % of patients received multimodal management (surgery n = 50, radiotherapy n = 37, chemotherapy n = 30). Among 42 patients with limb ES, 9 (21 %) underwent amputation, and isolated limb perfusion (ILP) was required in 17 (40.5 %) to allow conservative management. Among the 45 patients who underwent conservative surgery, flap reconstructions were required in 13 (28.8 %). The median follow-up was 5.7 years. The 5-year actuarial OS rates were 54, 62, and 24 % in the entire group and the M0 and M1 groups, respectively. In the M0 group, the 5-year actuarial distant control, local control (LC), and locoregional control rates were 67, 75, and 66 %, respectively. Prognostic factors for poor OS in the multivariate analysis were tumors that were deep to the fascia (p = 0.04) and grade 3 (p = 0.005). In the univariate analysis, age <30 years (p = 0.04), the T2 stage (p = 0.04), and mass presentation (p = 0.03) correlated with decreased LC, whereas patients who underwent ILP had a significantly higher LC rate (hazard ratio 3; 95 % confidence interval 0.9-9.4; p = 0.05).
CONCLUSIONS: Multimodal management including ILP and flap reconstruction is necessary to achieve optimal conservative LC. High rates of metastasis and lymphatic spread require innovative systemic treatments.

Entities:  

Mesh:

Year:  2013        PMID: 24046109     DOI: 10.1245/s10434-013-3247-4

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  9 in total

1.  Clinical outcomes of patients with epithelioid sarcomas: impact and management of nodal metastasis.

Authors:  Hidetatsu Outani; Yoshinori Imura; Takaaki Tanaka; Satoshi Takenaka; Kazuya Oshima; Kenichiro Hamada; Shigeki Kakunaga; Susumu Joyama; Norifumi Naka; Ikuo Kudawara; Takafumi Ueda; Nobuhito Araki; Hideki Yoshikawa
Journal:  Int J Clin Oncol       Date:  2017-08-10       Impact factor: 3.402

2.  Clinical features and outcomes of young patients with epithelioid sarcoma: an analysis from the Children's Oncology Group and the European paediatric soft tissue Sarcoma Study Group prospective clinical trials.

Authors:  Sheri L Spunt; Nadine Francotte; Gian Luca De Salvo; Yueh-Yun Chi; Ilaria Zanetti; Andrea Hayes-Jordan; Simon C Kao; Daniel Orbach; Bernadette Brennan; Aaron R Weiss; Max M van Noesel; Lynn Million; Rita Alaggio; David M Parham; Anna Kelsey; R Lor Randall; M Beth McCarville; Gianni Bisogno; Douglas S Hawkins; Andrea Ferrari
Journal:  Eur J Cancer       Date:  2019-04-05       Impact factor: 9.162

Review 3.  Epithelioid Sarcoma: Opportunities for Biology-Driven Targeted Therapy.

Authors:  Jonathan Noujaim; Khin Thway; Zia Bajwa; Ayeza Bajwa; Robert G Maki; Robin L Jones; Charles Keller
Journal:  Front Oncol       Date:  2015-08-17       Impact factor: 6.244

4.  Early clinical and metabolic response to tazemetostat in advanced relapsed INI1 negative epithelioid sarcoma.

Authors:  Ghazal Tansir; Sameer Rastogi; Shamim Ahmed Shamim; Adarsh Barwad
Journal:  Future Sci OA       Date:  2021-01-12

Review 5.  Beyond SMARCB1 Loss: Recent Insights into the Pathobiology of Epithelioid Sarcoma.

Authors:  Elisa Del Savio; Roberta Maestro
Journal:  Cells       Date:  2022-08-24       Impact factor: 7.666

6.  An SS18::NEDD4 cutaneous spindled and epithelioid sarcoma: An hitherto unclassified cutaneous sarcoma, resembling epithelioid sarcoma with aggressive clinical behavior.

Authors:  Ashley Patton; Steve Oghumu; O Hans Iwenofu
Journal:  Genes Chromosomes Cancer       Date:  2022-06-15       Impact factor: 4.263

Review 7.  Epithelioid Sarcoma of the External Auditory Canal: An Uncommon Tumor at an Unusual Site and a Brief Overview of the Literature.

Authors:  Bingcheng Wu; Joshua Kai Xun Tay; Woei Shyang Loh; Fredrik Petersson
Journal:  Head Neck Pathol       Date:  2021-01-04

8.  Primary rhabdoid epithelioid sarcoma of the left thigh mimicking epithelioid rhabdomyosarcoma: A diagnostic pitfall.

Authors:  Rahadyan Magetsari; Ery Kus Dwianingsih; Yuni Artha Prabowo Putro; Irene Araneta; Yudha Mathan Sakti
Journal:  Int J Surg Case Rep       Date:  2020-05-08

9.  Prospective evaluation of intensity-modulated radiotherapy toxicity in extremity soft tissue sarcomas patients: A role for irradiated healthy soft tissue volume?

Authors:  Rémi Bourdais; Samir Achkar; Charles Honoré; Matthieu Faron; Andrea Cavalcanti; Guillaume Auzac; Carine Ngo; Leila Haddag-Miliani; Benjamin Verret; Sarah Dumont; Eric Deutsch; Axel Le Cesne; Olivier Mir; Cécile Le Péchoux; Antonin Levy
Journal:  Clin Transl Radiat Oncol       Date:  2021-06-04
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.